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Background: Thymidine kinase 1 (TK1) is a deoxyribonucleic acid (DNA) precursor enzyme and a proliferation
biomarker used for prognosis and treatment monitoring of breast cancer in humans. The aim was to determine if
serum thymidine kinase 1 (sTK1) activity and sTK1 protein levels in dogs with mammary tumors could be useful in
veterinary medicine.
Results: Serum samples from 20 healthy dogs and 27 dogs with mammary tumors were analyzed for sTK1 activity,
using an [3H]-deoxythymidine (dThd) phosphorylation assay, and for sTK1 protein levels by immune affinity/Western
blot assay. The molecular forms of sTK1 in acute lymphocytic leukemia (ALL), canine mammary tumor (CMT), and
healthy sera were determined by size exclusion chromatography.
Mean sTK1 activities in CMT were 1.0 ± 0.36 pmol/min/mL, differing significantly from healthy dogs
(mean ± SD = 0.73 ± 0.26 pmol/min/mL). Serum TK1 protein (26 kDa polypeptide) levels were also significantly
higher in CMTs compared to healthy dogs (mean ± SD = 28.5 ± 11.4, and 8.5 ± 4 ng/mL, respectively). Cellular TK1
isolated from ALL tumor cells was predominantly a dimer, while the serum TK1 activity eluted as a high molecular
weight (MW) oligomer. In analyses of CMT tissue extracts, TK1 activity eluted in two peaks, a minor peak with a
high MW oligomer and a major tetramer peak. Western blot analysis of chromatographic fractions showed that
cellular TK1 protein in both ALL and CMT dogs, and to some extent serum TK1 from ALL dogs, correlated with
activity profiles, but a large fraction of inactive TK1 protein was detected in CMT.
Conclusions: Serum TK1 protein and activity levels were significantly higher in CMT than in healthy dogs. Size
exclusion chromatography demonstrated major differences in the molecular forms of sTK1 in ALL, healthy, and
CMT dogs, with a large fraction of inactive TK1 protein in CMT. Our results showed that the sTK1 protein assay can
differentiate benign tumors (early stage tumors) from healthy more efficiently than sTK1 activity assay. This
preliminary data supports that sTK1 protein assay is clinically useful. Further studies are needed to evaluate the
diagnostic or prognostic role of serum TK1 protein in CMTs.
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Mammary tumors are the most common form of canine
tumors and account for approximately 50% of all tumors
in female dogs [1,2]. Development of canine mammary
tumors (CMTs) is influenced by age, hormone and genetic
predispositions. CMTs are commonly seen in bitches at
middle and old age, with a median age of 8–10 years [3-5].
Purebreed dogs have higher incidence of CMT [6] and
breeds like Poodles, English Springer Spaniels (ESSs),
German Shepherds, Boxers, and Dachshunds have a
higher risk of developing CMT [1]. Overall, human and
dog cancer diseases show similarities in terms of the
role of steroidal hormones during tumor development,
and correlation between tumor grade and rate of metas-
tasis [7,8]. A recent study has shown that variations in
the BRCA1 and BRCA2 genes are associated with CMT
in ESSs [9] and these genes are responsible for early on-
set of breast cancer in women. Inherited mutations in
BRCA1 or BRCA2 increase the risk of breast cancer in
women by around 56–84% [10,11]. The clinical impact
and outcome of having BRCA mutations is somewhat
unclear in humans [12-15]. BRCA1-associated breast
cancers often occur in younger women, and these tu-
mors are high grade and lack estrogen receptors (ERs),
and are often triple-negative and, as such, harder to treat
[16]. In dogs, overexpression of BRCA1 and BRCA2 has
been found in mammary adenocarcinomas and their
lymph node metastases, hence implying a tendency to
reflect grade of malignancy [17]. Nevertheless, compara-
tive breast cancer studies are likely to greatly benefit both
human and veterinary medicine.
Early detection of CMTs and efficient therapy can
increase the life span in dogs [18-20]. Several tumor
markers, such as carbohydrate antigen 15–3 (CA 15–3),
thymidine kinase 1 (TK1), carcinoembryonic antigen
(CEA), estrogen receptor (ER), and human epidermal
growth factor receptor 2 (HER-2/neu), have been eval-
uated for their capacity to aid in the diagnosis, prog-
nosis, and monitoring of breast cancer in humans
[21-24]. Some of these markers, like CA 15–3, CEA,
ER, and HER–2, have been clinically evaluated in dogs
[25-27], but investigations on TK1 in CMTs are largely
lacking.
Thymidine kinase (TK) is a cytosolic enzyme that
catalyzes the conversion of deoxythymidine (dThd) to
deoxythymidine monophosphate (dTMP), which is subse-
quently phosphorylated to di- and triphosphates via the
salvage pathway [28]. Thymidine kinase 1 is cell cycle-
dependent and S phase-specific. The TK1 activity reaches
a peak G1/S boundary and then decreases rapidly in G2
and becomes undetectable in M phase [29,30]. In human
medicine, serum TK1 (sTK1) activity level serves as
biomarker for prognosis and monitoring treatment of
lymphoma and leukemia [31-33]. Serum TK1 activity hasbeen determined by using the commercially available
TK-radioenzyme assay (REA) [34] and non-radiometric
TK-Liaison assay [35]. These activity-based assays provide
valuable information regarding prognosis and treatment
monitoring in canine lymphoma and leukemia [35,36]. A
recent study on sera from dogs with solid tumors demon-
strated that determination of sTK1 protein levels with im-
munochemical methods gave higher sensitivity compared
to TK1 activity measurements [37].
To date, no studies exist where both TK1 activity and
TK1 protein levels have been determined in sera from
CMT patients. In this study, we analyzed TK1 activity
and TK1 subunit 26 kDa protein levels in sera from 27
dogs with CMTs. We further characterized the molecular
forms of TK1 in ALL, CMT, and healthy dog sera using
size exclusion chromatography. In the case of ALL, it was
possible to study the cellular form of TK1 isolated from
the leukemic cells, as in the CMT tissue extract. To
our knowledge, this is the first time that cellular and




Sera from healthy dogs and dogs with mammary tumors
were collected from the University Animal Hospital at
the Swedish University of Agricultural Sciences, Uppsala,
Sweden, and stored at −20°C until analysis. The project
was approved by the Swedish Animal Ethics Committee
and owner consent was collected for each patient. The
study comprised samples from healthy dogs (n = 20) and
dogs with mammary tumors (n = 27: benign n = 11, malig-
nant n = 13, and unclassified (UC) n = 3). The mean and
median age was 6 years (range 3–10 years) for the healthy
group, and 9.5 and 9 years (range 3–14 years) for dogs
with mammary tumors.
The tumor diagnostic procedures were as described
previously [35]. A total of 20 breeds were included in
this study. The most common breeds included were
Labrador Retriever, Rottweiler, Boxer, and German
Shepherd (5/47 of each), followed by Golden Retriever
and Riesenschnauzer (4/47 each) Rhodesian Ridgebacks
and mixed breed (3/47 of each), Bernese Mountain Dog
and ESS (2/47 of each), Field Spaniel, Flatcoated Retriever,
Border Collie, American Cocker Spaniel, Welsh Springer
Spaniel, Belgian Shepherd, Dalmatian, Dachshund, and
Greyhound (1/47 of each). Polyclonal antibodies were pro-
duced against different epitopes in the C-terminal region
of dog TK1. The 28-mer antibody was produced using a
28 amino acid synthetic peptide (amino acids 195–223) as
antigen (Agrisera AB, Umeå, Sweden). The 16-mer anti-
body was produced against a 16 amino acid C-terminal
region (amino acids 211–225) (GenScript, Piscataway, NJ,
USA) [38].
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preparation of cell extract
An amount of 4 ml of heparinized ALL patient blood was
diluted with an equal part of sterile phosphate-buffered
saline (PBS) and the diluted blood sample was mixed
with an equal volume of Ficoll-Paque. This was followed
by centrifugation for 30 minutes at 1,500 revolutions per
minute (RPMs). The cell band was removed, and washed
three times with RPMI 1640 medium with L-glutamine
containing 20% fetal calf serum (FCS) and 50 μg/ml genta-
micin. The cell preparation contained at least 95% ALL
cells with a viability of >98%. Cell viability was estimated
by using the Trypan blue exclusion assay. If the cells take
up trypan blue it indicates that the cells are non-viable.
Cell viability should be at least >95% for healthy log-phase
cells in cultures. Percentages of viable cells were deter-
mined by using the following formula:
% viable cells
¼ 1:00 – Number of blue cells  Number of total cellsð Þ½ 
 100:
Cells (16 × 106) were lysed in buffer containing 10 mM
Tris/HCl, pH 7.6, 13.7 mM NaCl, 7 mM ethylenediamine-
tetraacetic acid (EDTA), 0.5% NP-40, and 2 mM 4-2(ami-
noethyl)benzenesulfonyl fluoride hydrochloride (Pefabloc,
Fluka, Seelze, Switzerland) for 30 minutes at 4°C. The sus-
pension was centrifuged at 13,000 RPMs for 10 minutes at
4°C and supernatant was stored in aliquots at −80°C after
addition of 20% of glycerol. Protein concentration in the
supernatant (4 mg/mL) was determined using the Bio-Rad
assay.
Extraction of thymidine kinase 1 from canine mammary
tumor tissue
Three grams of fresh tumor tissue (from dog No. 23)
were collected from the clinic in sterile PBS, pH 7.6.
The accuracy of the tumor diagnosis was confirmed by
histopathological analysis of two flanking tissue prepara-
tions right adjacent to the tissue used for TK1 analysis.
The TK1 enzyme extract was prepared as follows: The
tissue was homogenized in a Teflon homogenizer with
two volumes of 0.05 M Tris-HCI buffer, pH 8.0, con-
taining 0.34 M sucrose, 25 mM KCI, 5 mM MgCI2,
7 mM EDTA, 0.5% NP-40, and 2 mM 4-2(aminoethyl)
benzenesulfonyl fluoride hydrochloride (Pefabloc, Fluka,
Seelze, Switzerland). The homogenate was centrifuged
at 20,000 RPMs for 30 minutes. The supernatant with a
protein concentration of 3 mg/mL was stored at −20°C
for further analysis.
Serum thymidine kinase activity assay
Thymidine kinase 1 activity in serum samples was deter-
mined using an optimized [3H]-dThd phosphorylation
assay, as described previously [36]. In brief, this assay isbased on a radio enzymatic technique in which the
substrate 3[H]-thymidine is converted to 3[H]-thymidine
monophosphate by TK1 in serum. The TK1 activity is
expressed as pmol of dTMP formed per minute per mL of
serum.
Immunoaffinity Sepharose preparation
The purified polyclonal anti-dog TK1 antibody (16-mer)
was coupled to cyanogen bromide (CNBr)-activated
Sepharose 4B, as described previously [37]. Briefly, 2 mg
of purified 16-mer antibody was added per 1 g of the
CNBr-activated Sepharose 4B resin in 0.1 M sodium bi-
carbonate (NaHCO3, pH = 8.3) on agitation for 4 hours
at room temperature. Then the coupled Sepharose was
transferred into Tris–HCl buffer (0.1 M, pH 8.0) after
2 hours at room temperature. The resin was washed al-
ternately three times with acetate buffer (0.1 M, pH 4.0)
and Tris–HCl buffer (0.1 M, pH 8.0). The coupled
antibody-Sepharose was mixed with Tris-buffered saline
(TBS) containing 0.01% NaN3 1:1, and stored at 4°C.
Size exclusion chromatography
Size exclusion chromatography was performed as de-
scribed elsewhere [38,39] using a Superose 12 column
(1.0 × 30 cm; GE Healthcare, Uppsala, Sweden) attached
to fast protein liquid chromatography (FPLC) equipment
(GE Healthcare, Uppsala, Sweden). Acute lymphocytic
leukemia cell extract, ALL sera (100 μl), CMT tissue
extract, CMT sera (from dog No. 23), and sera from a
healthy dog (No. 5) (200 μl) were diluted in hydroxyethyl-
piperazineethane-sulfonic acid (HEPES), pH 7.6, buffer
(0.01 M) (NH4Cl, 0.15 M, and NaN3, 0.02%) and applied
on the column. Standard proteins were α2-macroglobulin,
720 kDa; β-amylase, 200 kDa; bovine serum albumin
(BSA), 66 kDa; ova albumin, 45 kDa; and horse myosin,
17 kDa.
Thymidine kinase 1 (TK1) isolation by anti-TK1 antibody
Sepharose
Dog recombinant TK1 (0.5–4 ng), 60 μL, serum samples
were diluted with TBS, pH 7.6, to a final volume of
230 μL. Next, 300 μL of FPLC fractions were incubated
with anti-dog TK1 antibody Sepharose (70 μL of a
1:1 V/V mixture of antibody Sepharose and TBS). The
samples were agitated at 4°C for 4 hours, followed by
centrifugation for 1 minute at 13,000 RPMs. The anti-
body Sepharose was washed twice with TBS, once with
TBS-Tween, and once more with TBS. Then, 30 μL of
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) sample buffer (containing Tris–HCl, pH 6.8,
0.5 M; glycerol, 20%; (w/v) SDS, 10%; bromophenol blue,
0.1%; and dithiothreitol (DTT), 10 mM) was added to the
Sepharose before incubation at room temperature for
20 minutes, followed by centrifugation as above. The




Figure 1 Standard curve for recombinant TK1 protein using
the immune affinity assay and Western blot analysis. (A)
Concentration curve obtained after scanning the relative band
intensities (arbitrary units (AUs)). (B) The 28 kDa polypeptide
bands of recombinant dog thymidine kinase 1 (TK1) (0.5–4 ng).
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subjected to 12% SDS-PAGE, followed by electrophor-
etic transfer and Western blotting, as described previ-
ously [37,38].
Statistical analysis
The TK1 activity and protein distribution in both groups
were tested for normality using the D’Agostino and Pearson
omnibus normality test. The majority of distributions
were Gaussian and we used one way analysis of variance
(ANOVA) followed by Tukey’s multiple comparison
post test to compare TK1 values across multiple groups.
Pearson correlation coefficient (r) was used to deter-
mine the correlation between TK1 activities and TK1
protein levels. Unpaired t-test was used to evaluate the
difference between the groups. For sensitivity and speci-
ficity analysis and for comparison of assays, receiver op-
erating characteristic (ROC) curves were constructed.
Statistical analyses were performed using Graph Pad
Prism 5.0 (Graph Pad Software, La Jolla, CA, USA). The
level of significance was set at P < 0.05.
Results
Serum thymidine kinase 1 activity and protein levels in
canine mammary tumor
Sera from 20 healthy dogs and 27 CMT dogs were ana-
lyzed for sTK1 activity and sTK1 protein, as described in
the Materials and Methods section. The intensities of the
28 kDa recombinant dog TK1 polypeptide (0.5–4 ng) were
analyzed and a standard curve was created, as shown in
Figure 1. Serum TK1 protein levels in clinical samples
were calculated using this curve. In the healthy group,
sTK1 activity was in the range of 0.4–1.4 pmol/min/mL,
with a mean ± standard deviation (SD) of 0.73 ± 0.26
(Table 1). In the immunoaffinity/Western blot analysis,
faint bands were detected in sera from healthy dogs,
with a range of 3–18 ng/mL (mean ± SD of 8.5 ± 4 ng/mL;
Figure 2A). In the CMT group, the sTK1 activity was
0.5–2.5 pmol/min/mL (mean ± SD = 1.0 ± 0.36). High
sTK1 protein levels were found in the mammary tumor
sera (Figure 2B) and the sTK1 protein concentration
ranged from 9 ng/mL to 54 ng/mL (mean ± SD of 28.5 ±
11.4; Table 2). Serum TK1 protein levels in the ALL serum
(36 ng/mL; Figure 2C), ALL extract (20 ng/mL; Figure 2D),
and CMT extract (34 ng/mL; Figure 2E) were also
determined.
Significant differences were found in mean sTK1 activity
(P = 0.007; Figure 3A) and sTK1 protein levels (P < 0.0001;
Figure 3B) between healthy and CMT dogs. Significant
correlations were also found between the sTK1 activity
and sTK1 protein levels in healthy dogs (r = 0.52, P = 0.01)
and CMTs (r = 0.41, P = 0.03). Canine mammary tumors
were further classified as benign or malignant and the
sTK1 protein and activity levels were determined in thesesubgroups and compared to those in healthy dogs. There
was no significant difference in sTK1 activity in sera from
healthy, benign, and malignant dogs (Figure 3C). However,
a significant difference was found in sTK1 protein levels
between these subgroups (Figure 3D). To evaluate the per-
formance of the two different assays, ROC curve analysis
for CMTs vs. healthy dogs was done. The results showed
that TK1 activity assay had an area under the curve
(AUC) of 0.74, P = 0.0048 (95% confidence interval (CI)
0.59–0.88), with a cutoff value of 1.32 pmol/min/mL,
sensitivity of 0.22, and specificity of 0.95 (Figure 4A).
The TK1 protein assay, however, had an AUC of 0.96,
P < 0.0001 (95% CI 0.92–1.01). The sensitivity in this
case was 0.81 and the specificity 0.95, using a cutoff
value of 17.5 ng/mL (Figure 4B). The specific activity
of sTK1 (nmol dTMP/min/mg of sTK of 26 kDa), based
on the immunoaffinity assay and 3[H]-dThd activity mea-
surements in healthy dogs, was 49 ± 21 nmol/min/mg,
which is significantly higher (P < 0.0001) compared to sera
from the CMT group (20 ± 11 nmol/min/mg). The higher
sTK1 specific activity in healthy dogs (about 2.5-fold),
compared to dogs with CMTs, means that there is a larger
fraction of inactive TK1 polypeptide in case of CMTs.
Molecular forms of thymidine kinase 1 in acute
lymphocytic leukemia extract and sera
A fresh blood sample collected from a dog with ALL
and white blood cells were separated, as described in the
Materials and Methods section. Cellular extract and sera
Table 1 Serum thymidine kinase 1 (sTK1) activity and sTK1 protein concentration in sera from healthy dogs
sTK1 activity sTK1 concentration
Number Breed Age (yrs) (pmol/min/mL) (ng/mL)
(Mean ± SD)a (Mean ± SD)b
1 Labrador Retriever 8 0.7 ± 0.03 3 ± 1
2 Bernese Mountain Dog 10 1.0 ± 0.05 9 ± 3
3 Labrador Retriever 5 0.5 ± 0.04 4 ± 2
4 Golden Retriever 6 0.4 ± 0.02 7 ± 3
5 Golden Retriever 5 1.0 ± 0.06 15 ± 4
6 German Shepherd 6 1.0 ± 0.1 11 ± 3
7 Riesenschnauzer 7 0.5 ± 0.02 4 ± 2
8 Mixed breed 6 0.5 ± 0.05 12 ± 5
9 Riesenschnauzer 8 0.6 ± 0.04 10 ± 4
10 German Shepherd 6 0.7 ± 0.08 12 ± 3
11 Rottweiler 5 0.5 ± 0.03 7 ± 3
12 English Springer Spaniel 3 1.3 ± 0.09 8 ± 2
13 Riesenschnauzer 7 1.4 ± 0.12 13 ± 4
14 Labrador Retriever 5 0.8 ± 0.07 18 ± 5
15 Labrador Retriever 6 0.7 ± 0.03 5 ± 3
16 Mixed breed 6 0.6 ± 0.01 9 ± 2
17 Bernese Mountain Dog 5 0.7 ± 0.04 8 ± 3
18 Dalmatian 6 0.5 ± 0.03 4 ± 2
19 Labrador Retriever 4 0.7 ± 0.11 8 ± 3
20 Golden Retriever 6 0.5 ± 0.04 6 ± 2
aMean values of three observations from a single measurement occasion. bMean values of two observations from two independent experiments.
SD = standard deviation.
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Figure 2 Immunoaffinity and Western blot results for sera from healthy dogs (A), dogs with canine mammary tumors (CMTs) (B), and a
dog with acute lymphocytic leukemia (ALL) (C). The Figure shows the TK1 band determined in the ALL cell extract (D) and a CMT (M-23)
tissue extract (E).
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Table 2 Serum thymidine kinase 1 (sTK1) activity and protein levels in sera from dogs with mammary tumors
sTK1 activity sTK1 concentration
Number Breed Age (yrs) Diagnosis (pmol/min/mL) (ng/mL)
(Mean ± SD)a (Mean ± SD)b
1 Field Spaniel 9 Mammary adenoma 0.8 ± 0.04 26 ± 4
2 Rhodesian Ridgeback 11 Mammary adenoma 0.9 ± 0.03 26 ± 5
3 Rhodesian Ridgeback 3 Mammary adenoma 0.6 ± 0.02 23 ± 3
4 Boxer 13 Mammary carcinoma 0.9 ± 0.04 27 ± 2
5 American Cocker Spaniel 11 Mammary carcinoma 0.9 ± 0.05 27 ± 5
6 Boxer 9 Mammary carcinoma 0.6 ± 0.03 21 ± 4
7 Welsh Springer Spaniel 9 Mammary carcinoma 1.6 ± 0.11 54 ± 8
8 English Springer Spaniel 10 Mammary adenoma 1.5 ± 0.14 35 ± 5
9 German Shepherd 7 Mammary carcinoma 0.7 ± 0.03 23 ± 3
10 Belgian Shepherd 9 UC 0.5 ± 0.01 17 ± 3
11 Riesenschnauzer 14 Mammary carcinoma 0.9 ± 0.02 30 ± 3
12 Boxer 11 Mammary adenoma 1.4 ± 0.1 27 ± 4
13 Boxer 7 Mammary carcinoma 1.2 ± 0.15 31 ± 5
14 Rottweiler 9 Mammary adenoma 0.5 ± 0.02 12 ± 3
15 German Shepherd 11 Mammary adenoma 0.8 ± 0.03 39 ± 6
16 Dachshund 9 Mammary carcinoma 0.9 ± 0.04 49 ± 5
17 Greyhound 12 UC 1.8 ± 0.18 28 ± 4
18 Rhodesian Ridgeback 11 Mammary adenoma 1.0 ± 0.06 17 ± 3
19 Rottweiler 10 Mammary adenoma 0.9 ± 0.05 28 ± 2
20 Boxer 8 UC 0.7 ± 0.04 9 ± 2
21 Rottweiler 10 Mammary carcinoma 0.9 ± 0.04 40 ± 8
22 Rottweiler 7 Mammary adenoma 0.7 ± 0.05 18 ± 5
23 German Shepherd 10 Mammary carcinoma 1.3 ± 0.08 31 ± 7
24 Golden Retriever 8 Mammary carcinoma 1.5 ± 0.12 43 ± 9
25 Flatcoated Retriever 6 Mammary adenoma 1.0 ± 0.09 28 ± 5
26 Mixed breed 6 Mammary carcinoma 1.1 ± 0.08 49 ± 10
27 Border Collie 14 Mammary carcinoma 1.6 ± 0.14 13 ± 4
aMean values of three observations from a single measurement occasion. bMean values of two observations from two independent experiments. SD = standard
deviation. Mammary tumors are classified as adenoma (benign), carcinoma (malignant), and UC = unclassified.
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column and the TK1 activity and protein levels in the
fractions were determined. Native cellular TK1 activity
eluted as major peak with molecular weights (MWs) of
40–66 kDa, but with a small peak and some enzyme ac-
tivity in the fractions at the higher MW range (Figure 5A).
Western blot analysis of cellular extract fractions showed
a TK1 subunit (26 kDa) in the fractions eluted, corre-
sponding to MWs of 40–66 kDa, with faint bands in the
high MW region (Figure 5B). When analyzing sera from
the same dog, about 90% of TK1 eluted as a peak in
the high MW range corresponding to 200–720 kDa
(Figure 5C). A TK1 polypeptide of 26 kDa was detected in
fractions 1–12, but the band intensity did not correlate
with the activity levels in these fractions (Figure 5D).These results indicate that active cellular TK1 isolated
from ALL exists mainly as dimer, while active sTK1 from
the same dog was found to occur as a high MW oligomer.
A gel filtration experiment has been carried out with sera
from another ALL dog and similar results were found
(data not shown).
Molecular forms of thymidine kinase 1 in mammary
tumor extract and sera
Tissue extract prepared from a CMT patient (No. 23)
was applied on the Superose 12 column and around 70%
of total TK1 activity eluted as major peak with MWs of
40–100 kDa, but with a minor peak and some enzyme
activity in the fractions corresponding to higher MW




Figure 3 Serum TK1 activity and TK1 protein concentrations in different clinical samples. (A) Serum thymidine kinase 1 (sTK1) activity
(pmol/min/mL) in sera from healthy dogs (•) and dogs with mammary tumors (■). The error bars represent means ± standard deviation (SD). (B)
Serum TK1 protein levels in sera from healthy dogs (•) and dogs with canine mammary tumors (CMTs) (■). (C) Comparison of sTK1 activity in
healthy dogs (•) and dogs with benign (■) and malignant (▲) CMTs. (D) Comparison of sTK1 protein levels in healthy dogs (•) and dogs with
benign (■) and malignant (▲) mammary tumors. The error bars represent means ± standard deviation (SD).
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to the peak and faint bands in the high MW region
(Figure 6B). A serum sample from the same CMT dog
was also analyzed and more than 95% of the total TK1
activity eluted in fractions 1–11, corresponding to the
MW range 200–720 kDa (Figure 6C). Thymidine kinase 1
polypeptide of 26 kDa was detected in all fractions
(Figure 6D) and there was no correlation with TK1




Figure 4 Receiver operating characteristic (ROC) curve for the serum
(A) sTK1 activity. (B) sTK1 protein assay results.in multimeric forms in CMT (oligomers, dimers, and
tetramers), many of them apparently inactive.
Molecular forms of thymidine kinase 1 in healthy dog sera
A serum sample from a healthy dog (No. 5) was subjected
to size exclusion chromatography. Thymidine kinase 1 ac-
tivity was recovered as a single peak in fractions 1–5, cor-
responding to a MW range of 500–720 kDa (Figure 7A).




thymidine kinase 1 (sTK1) in healthy and canine mammary sera.
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Figure 5 Acute lymphocytic leukemia (ALL) cell extract and serum analyzed by Superose 12 column chromatography. (A) The thymidine
kinase 1 (TK1) activity in the fractions from the ALL cell extract (•). (B) Western blot analyses of the same fractions. (C) Serum TK1 (sTK1) activity in the
fractions from the ALL dog (•). (D) Western blot analyses and sTK1 protein in the same fractions. Arrows indicate the elution position of the molecular
weight (MW) markers.
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strate that sTK1 exists as an active high MW oligomer in
sera of healthy dogs. When we analyzed another healthy
dog serum on superose 12 column, similar results were
found (Figure 8).
Discussion
Serum TK1 determinations have been used clinically for
many years as they provide valuable information to guide2 4 6 8 10 12 14 16 18 20 22 24




Figure 6 Canine mammary tumor (CMT) (dog No. 23) tumor tissue extr
(A) Thymidine kinase 1 activity in the fraction from the CMT tissue extract (•).
activity in the fractions from the CMT serum (•). (D) Western blot analyses of t
weight (MW) markers. Numbers represent the fast protein liquid chromatograanti-cancer therapy both in human and in veterinary
medicine. Development of antibody-based assays has ex-
tended the use of TK1 in human breast cancer. Some
studies in humans have shown that breast cancer sera
contain high sTK1 protein levels, which can serve as prog-
nostic marker for early stage detection [24,40,41]. A recent
study in dogs with solid tumors has shown that TK1 pro-
tein assays are more sensitive compared to TK1 activity
assays [37]. Mammary tumors occur more frequently in2 4 6 8 10 12 14 16 18 20 22 24




act and serum analyzed by Superose 12 column chromatography.
(B) Western blot analyses of the same fractions. (C) Thymidine kinase 1
he same fractions. Arrows indicate the elution position of the molecular
phy (FPLC) fractions.
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Figure 7 Serum from a healthy dog (No. 5) analyzed by Superose
12 column chromatography. (A) Serum thymidine kinase 1 (sTK1)
activity in the fractions from the healthy dog (•). (B) Western blot
analyses of sTK1 protein in the same fractions. Arrows indicate the
elution position of the molecular weight (MW) markers. Numbers
represent the fast protein liquid chromatography (FPLC) fractions.
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early stages of disease will be valuable clinically. In this
study, we evaluated if sTK1 activity assay and TK1 protein
assay can effectively differentiate CMT patients from
healthy dogs.A)
B)
2 4 6 8 10 12 14 16 18 20 22
Figure 8 STK1 profile in FPLC fractions of another healthy dog
(sample no. 14, See Table 1) (A) Serum thymidine kinase 1 (sTK1)
activity in the fractions from the healthy dog (•). (B) Western blot
analyses of sTK1 protein in the same fractions. Arrows indicate the
elution position of the molecular weight (MW) markers. Numbers
represent the fast protein liquid chromatography (FPLC) fractions.The reason for comparing ALL and CMT was to
show the difference in the molecular forms of TK1 in
Hematological tumors (ALL) and solid tumors (CMT).
In our last published study [38] we demonstrated the
molecular forms of STK1 in an ALL patient and it was
hence highly interesting to repeat these studies together
with a characterization of the molecular forms of cellular
(i.e. the tumor cells) TK1 from the same ALL patient. Fur-
thermore, CMT are the most common tumors in older
dogs and to develop an assay that can aid in the diagnosis
of these types of tumors would be highly clinically valuable.
Even though sTK1 activity levels in CMTs significantly
differ from levels in healthy dogs, there is a large overlap
between levels in the two groups. The results presented
here using sTK1 protein assays showed a larger differ-
ence and CMT patients had significantly higher sTK1
protein levels compared to healthy dogs. In this study,
sTK1 protein assays were apparently able to differentiate
benign from healthy samples as well as benign from the
malignant forms of CMT, indicating that it may be pos-
sible to predict tumor progression by measuring sTK1
protein levels. Furthermore, the ROC curve analysis
showed that the sTK1 protein assay had a sensitivity of
0.81, while the sTK1 activity assay showed a sensitivity
of 0.22. Consequently, the sTK1 protein assay is most
likely very valuable for establishing prognosis and early
diagnosis in CMTs. Recently, expression analyses in CMTs
have shown significant similarities to human breast cancer
[42]. Consequently, it is suggested that these profiles can
aid in prognosticating outcome [43,44]. However, these
expression analyses are still complicated and most likely
useful only as research tools. Moreover, they require
specific, non-routine tissue preparation. A simple protein
measurement in serum from a mammary tumor patient
would be significantly easier to use and have a direct clin-
ical implication. A natural next step in this research is
to investigate if TK protein levels are correlated to, e.g.,
BRCA status in canine mammary tumors [9] and, if so, if
TK protein level analysis is a suitable complement to
more elaborate expression analyses of extirpated tumor
tissue and is possible to perform before surgery. This
could become a marker to gate patients into more, or less,
aggressive surgical/medical interventions and could likely
positively affect outcomes. It could also reduce surgical
trauma in a fair portion of cases, which is ethically attract-
ive. In the present study no correlation was tested between
e.g. high/low grade in the CMT group because of low
power. It is known that half of the malignant CMT (later)
metastasize. Thus, it would be clinically highly beneficial if
an early indication of the metastatic potential of the indi-
vidual tumor could be made. The present study clearly
indicates the need for prospective follow-up studies, where
larger groups of CMTs are collected, with possibility to
collect follow-up information on clinical outcome and
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protein values to see if a decline in STK1 levels is seen
post-op, further indicating the correlation between STK1
levels and CMT.
However, a lack of more detailed information about
the molecular forms of sTK1 in dogs with tumor disease
is a problem when it comes to using TK1 as a biomarker.
In this study, we characterized cellular and serum forms
of TK1. The cellular TK1 in ALL cells was found to exist
mainly as active dimers, as reported previously [38,45],
while sTK1 occurs as high MW oligomeric complexes.
There was no direct correlation between sTK1 protein
and activity levels, as shown previously [38], and this was
apparently due to the different types of TK1 protein com-
plexes, with varying specific activity. Active TK1 in CMT
cell extracts was mainly found as tetramers, while sTK1
activity occurred predominantly as high MW oligomers.
The 26 kDa TK1 protein levels were correlated to the
activity in cell extract, but in case of sTK1, the 26 kDa
polypeptide was detected in all fractions corresponding
to a broad range of MWs. In sTK1 in healthy dogs,
where the levels were low, both TK1 activity and protein
were detected only in the high MW region. There is a
correlation between sTK1 activity and protein levels in
sera from healthy dogs (r = 0.52) and sera from dogs
with CMTs (r = 0.41). This is most likely because activity
assays measure the high MW complex of TK1, whereas
the TK1 protein assays measure both active high MW
and inactive lower MW forms. There was a difference in
the mean specific activities of sTK1 from healthy dogs,
dogs with CMT, and the dog with ALL, namely, 49 ± 21,
20 ± 10, and 760 ± 40 nmol/min/mg, respectively. The
results obtained in this study are similar to those described
earlier [37]. The specific activity of sTK1 was measured in a
relatively large group of dogs with CMT and was found to
be about half that of sTK1 in healthy dogs and about 2% of
that observed in the ALL dog, which is very close to results
observed with recombinant canine TK1 [38].
In this study, we have attempted to determine total
tumor TK1 protein and activity levels as well as sTK1
levels in ALL and CMT dogs, using the same methods.
There was a large difference in the ratio between the cel-
lular and sTK1 total activity and 26 kDa TK1 protein
levels in the ALL and CMT dogs (both about 50-fold).
The reason for these large differences is most likely related
to the differences in specific activities of the cellular and
serum form of TK1 and this in turn is linked to the mech-
anisms involved in the accumulation and release of TK1
from hematologic and solid tumors. However, further
studies are needed to clarify this question.
Normally, TK1 is present in relatively low concentrations
in blood from healthy dogs. It is 5–20-fold in malignant
diseases [37,38]. Therefore, sensitive laboratory methods
are needed to obtain sufficient specificity and sensitivity.With the current available enzyme activity assays, this was
achieved only for hematological tumors. These enzyme
activity assays were not sufficient for detecting mammary
tumors in dogs. However, sTK1 protein assays differenti-
ate CMTs from healthy dogs more effectively and improve
the clinical precision. The work described here will help
to develop a reliable TK1 clinical test, which could be
valuable in veterinary medicine. Furthermore, with the
similarities to human mammary tumors, it will likely have
comparative implications in breast cancer research.
Conclusions
The results from this study show that TK1 protein assays
provide more clinically relevant information on CMTs
compared to TK1 activity assays. Size exclusion chroma-
tography analysis demonstrates that sTK1 exists as a high
MW complex form in dogs with ALL, healthy dogs, and
dogs with CMT, with active enzyme. In addition, in sera
from dogs with CMT, there is a large fraction of inactive
TK1 in intermediate and low MW complexes. These
results will help to develop better TK1 protein assays of
value for human and veterinary medicine.
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